GT200000224A - Composicion para el tratamiento de tejidos dañados. - Google Patents
Composicion para el tratamiento de tejidos dañados.Info
- Publication number
- GT200000224A GT200000224A GT200000224A GT200000224A GT200000224A GT 200000224 A GT200000224 A GT 200000224A GT 200000224 A GT200000224 A GT 200000224A GT 200000224 A GT200000224 A GT 200000224A GT 200000224 A GT200000224 A GT 200000224A
- Authority
- GT
- Guatemala
- Prior art keywords
- composition
- treatment
- growth factor
- inhibiting agent
- damaged fabrics
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000004744 fabric Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000003102 growth factor Substances 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION, EN PARTICULAR, A UNA COMPOSICION FARMACEUTICA. LA PRESENTE INVENCION TAMBIEN SE REFIERE A USOS DE ESA COMPOSICION, EN PARTICULAR, PARA EL TRATAMIENTO DE TEJIDOS DAÑADOS. DE ACUERDO CON LA PRESENTE INVENCION LOS TEJIDOS DAÑADOS TALES COMO LAS HERIDAS, PUEDEN TRATARSE DE FORMA MAS EFICAZ SI SE USA UNA COMBINACION DE UN FACTOR DE CRECIMIENTO COMO UN POLIPEPTIDO Y UN AGENTE INHIBIDOR, UNA PROTEASA O SU DERIVADO ESTANDO INVOLUCRADO ESPECIFICAMENTE CON LA PROTEINA EN DERREDOR DE LA HERIDA. LA COMBINACION DEL AGENTE INHIBIDOR Y EL FACTOR DE CRECIMIENTO ACTUAN SINERGICAMENTE. TIPICAMENTE PARA MEZCLAS TOPICAS O MEZCLAS INYECTADAS LOCALMENTE, LA RELACION RELATIVA ENTRE EL AGENTE INHIBIDOR Y EL FACTOR DE CRECIMIENTO PUEDE ESTAR COMPRENDIDA ENTRE 1000:1 Y 1:1. DE ACUERDO A LA INVENCION SE PROPORCIONA EL USO DE UNA COMPOSICION PARA EL TRATAMIENTO MEDICO DE HERIDAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9930768.8A GB9930768D0 (en) | 1999-12-29 | 1999-12-29 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200000224A true GT200000224A (es) | 2002-06-15 |
Family
ID=10867127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200000224A GT200000224A (es) | 1999-12-29 | 2000-12-22 | Composicion para el tratamiento de tejidos dañados. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1242120A2 (es) |
| JP (1) | JP2003519193A (es) |
| AR (1) | AR027122A1 (es) |
| AU (1) | AU1878201A (es) |
| CA (1) | CA2395487A1 (es) |
| CO (1) | CO5271671A1 (es) |
| EC (1) | ECSP003859A (es) |
| GB (1) | GB9930768D0 (es) |
| GT (1) | GT200000224A (es) |
| PE (1) | PE20011095A1 (es) |
| UY (1) | UY26514A1 (es) |
| WO (1) | WO2001049309A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| ATE544855T1 (de) | 2000-10-16 | 2012-02-15 | Genentech Inc | Wisp polypeptide, und deren therapeutische anwendungen |
| WO2003013569A2 (en) | 2001-07-27 | 2003-02-20 | The Board Of Regents, The University Of Texas System | Use of thrombin-derived peptides for the therapy of chronic dermal ulcers |
| WO2003029819A1 (en) * | 2001-09-28 | 2003-04-10 | Takeda Chemical Industries, Ltd. | Method of screening preventive/remedy for bone/joint diseases |
| WO2004014937A2 (en) | 2002-07-02 | 2004-02-19 | The Board Of Regents, The University Of Texas System | Thrombin peptide derivatives |
| AU2004312090B2 (en) | 2003-12-31 | 2008-08-14 | The Board Of Regents, The University Of Texas System | Pharmaceutical composition for thrombin peptide derivatives |
| CN101365715B (zh) * | 2005-10-07 | 2013-03-27 | P·安杰莱蒂分子生物学研究所 | 基质金属蛋白酶11疫苗 |
| WO2008060622A2 (en) * | 2006-11-15 | 2008-05-22 | Coda Therapeutics, Inc. | Improved methods and compositions for wound healing |
| KR101629504B1 (ko) * | 2014-04-14 | 2016-06-10 | 주식회사 엘지생활건강 | 사이토카인 조합을 함유하는 피부 상태 개선용 조성물 |
| JP2020517615A (ja) * | 2017-04-21 | 2020-06-18 | プレシゲン，インコーポレイテッド | 硬皮症の処置のための、マトリックス金属タンパク質分解酵素を含む自己由来細胞の送達 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01279840A (ja) * | 1988-04-28 | 1989-11-10 | Wakunaga Pharmaceut Co Ltd | 新規外用組成物 |
| GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
-
1999
- 1999-12-29 GB GBGB9930768.8A patent/GB9930768D0/en not_active Ceased
-
2000
- 2000-12-21 EP EP00981550A patent/EP1242120A2/en not_active Withdrawn
- 2000-12-21 WO PCT/IB2000/001935 patent/WO2001049309A2/en not_active Ceased
- 2000-12-21 CA CA002395487A patent/CA2395487A1/en not_active Abandoned
- 2000-12-21 JP JP2001549676A patent/JP2003519193A/ja not_active Withdrawn
- 2000-12-21 AU AU18782/01A patent/AU1878201A/en not_active Abandoned
- 2000-12-21 CO CO00097188A patent/CO5271671A1/es not_active Application Discontinuation
- 2000-12-22 GT GT200000224A patent/GT200000224A/es unknown
- 2000-12-27 AR ARP000106960A patent/AR027122A1/es not_active Application Discontinuation
- 2000-12-27 PE PE2000001405A patent/PE20011095A1/es not_active Application Discontinuation
- 2000-12-28 UY UY26514A patent/UY26514A1/es not_active Application Discontinuation
- 2000-12-28 EC EC2000003859A patent/ECSP003859A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2395487A1 (en) | 2001-07-12 |
| UY26514A1 (es) | 2001-07-31 |
| WO2001049309A3 (en) | 2002-02-28 |
| AR027122A1 (es) | 2003-03-12 |
| ECSP003859A (es) | 2002-09-27 |
| EP1242120A2 (en) | 2002-09-25 |
| WO2001049309A2 (en) | 2001-07-12 |
| JP2003519193A (ja) | 2003-06-17 |
| PE20011095A1 (es) | 2001-10-27 |
| AU1878201A (en) | 2001-07-16 |
| GB9930768D0 (en) | 2000-02-16 |
| CO5271671A1 (es) | 2003-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9702415A (es) | Extractos de cocoa antineoplastica y metodos para elaborar y usar los mismos. | |
| ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
| AR010701A1 (es) | Una composicion de tenido por oxidacion de las fibras queratinicas y procedimiento de tenido que utiliza esta composicion | |
| CO2021000174A2 (es) | Composiciones tópicas para el alivio del dolor | |
| BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
| AR005281A1 (es) | Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. . | |
| ES2063033T3 (es) | Empleo de igf-ii en el tratamiento de la enfermedades de los huesos. | |
| ECSP034444A (es) | Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina | |
| PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
| ES2157601T3 (es) | Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple. | |
| AR009676A1 (es) | Composicon lista para el empleo para el tenido por oxidacion de las fibras queratinicas, procedimiento de tenido que usa esta composicion, y dispositivo de varios compartimientos. | |
| ES2055677T1 (es) | Procedimiento de obtencion de una composicion para el tratamiento de la disfuncion erectil. | |
| GT200000224A (es) | Composicion para el tratamiento de tejidos dañados. | |
| AR008799A1 (es) | Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento | |
| MX2019014667A (es) | Tratamiento de trastornos cutaneos. | |
| ES2163795T3 (es) | Composicion farmaceutica contra los tumores e infecciones por papilomavirus. | |
| CO2022016153A2 (es) | Inhibidores de il4i1 y métodos de uso | |
| ES2137044T3 (es) | Utilizacion de derivados de oxazolidinona como agentes antipenetrantes en una composicion cosmetica y/o dermatologica. | |
| ES2133289T3 (es) | Aumento en los niveles de glutation con glutamina. | |
| ES2164899T3 (es) | Uso de alcaloides de la clase lamellarina en metodos de tratamiento. | |
| AR006892A1 (es) | Uso de formas del acido hialuronico (ha) para el tratamiento del cancer | |
| ES2129448T3 (es) | Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas. | |
| ES2133003T3 (es) | Utilizacion de al menos un glicol como agente de solubilizacion de la melatonina en agua y composiciones que los contienen. | |
| AR036009A1 (es) | Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica | |
| ES2185310T3 (es) | Agente antivirico herbario. |